PARP1 and ovarian carcinoma: FDA approved the PARP inhibitors olaparib and talazoparib in 2018/2019 for clinical treatment of refractory metastatic breast cancer with deleterious germline BRCA1/2 mutations, BRCA-mutated HER2-negative metastatic breast cancer, gBRCAm metastatic pancreatic cancer, and maintenance of BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancers [88,89].